News tagged with cyclosporine
Ciclosporin
Ciclosporin (INN/BAN) (pronounced /ˌsaɪkləˈspɔrɪn/), cyclosporine (USAN), cyclosporin (former BAN), or cyclosporin A is an immunosuppressant drug widely used in post-allogeneic organ transplant to reduce the activity of the immune system, and therefore the risk of organ rejection. Initially isolated from the fungus Tolypocladium inflatum isolated from a soil sample obtained by Sandoz scientists at Hardangervidda, Norway in 1969, ciclosporin is a cyclic nonribosomal peptide of 11 amino acids and contains a single D-amino acid, which are rarely encountered in nature.
For more information about Ciclosporin, read the full article at
Wikipedia.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
System to deliver organ transplant drug -- without harmful side effects
A new system for delivering a drug to organ transplant patients, which could avoid the risk of harmful side effects, is being developed by scientists at the University of Strathclyde in Glasgow.
Nanotechnology / Bio & Medicine
Jan 26, 2012 |
5 / 5 (1) |
0
Best post-transplant drug regimen identified for patients with new kidneys
For the thousands of patients who receive kidney transplants in the United States each year, preventing organ rejection without compromising other aspects of health requires a delicate balance of medications. Immunosuppresive ...
Jul 29, 2011 |
not rated yet |
0
Higher cancer rates found in liver transplant patients receiving cyclosporine for immunosuppression
Researchers at Erasmus MC University Medical Centre in The Netherlands found that cyclosporine treatment is a significant risk factor for the development of de novo cancer in liver transplant patients. Full details appear ...
Jun 24, 2010 |
not rated yet |
0
Transplant drug two-year study outcomes show superior kidney function
Two-year results from phase III clinical trials show the experimental immunosuppressive drug belatacept can better preserve kidney function in kidney transplant recipients while preventing graft rejection when compared with ...
Medicine & Health / Medications
May 03, 2010 |
not rated yet |
0
Cancer risk the same for kidney transplant recipients, no matter the drug
Drugs taken by kidney transplant recipients to prevent organ rejection carry similar risks of cancer, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The result ...
Apr 29, 2010 |
not rated yet |
1
New drug for kidney transplant recipients effective in humans
Initial results of a study conducted at 100 centers worldwide indicate that belatacept, a first-in-class costimulation blocker can prevent the immune system rejecting new organs. The results also suggest that it may provide ...
Feb 17, 2010 |
not rated yet |
0
Pain-free method of monitoring drug levels in transplant patients
The U.S. Patent and Trademark Office is reviewing a University of Rhode Island pharmacy professor's proposal to use saliva as a non-invasive way to monitor concentrations of anti-rejection drugs in patients that undergo transplants.
Apr 03, 2009 |
not rated yet |
0
Immunosuppressant medication may be cost-effective for dry eye syndrome
A topical eye emulsion consisting of cyclosporine (a medication used to reduce transplant rejections or to treat arthritis and psoriasis) may be a cost-effective treatment for dry eye syndrome that does not respond to other ...
Feb 09, 2009 |
5 / 5 (1) |
0
